New Chair for Medicines Australia
The Board of Medicines Australia today announced that it has appointed Dr Martin Cross as the new Chair of Medicines Australia.
“The Medicines Australia Board has unanimously agreed to appoint Dr Cross as Chair and looks forward to working with him to progress the issues of the innovative medicines industry in Australia,” said interim Medicines Australia Chair, Mark Fladrich.
“Dr Cross has a wealth of experience in the industry, recently working in the generics industry after more than 20 years working in the innovative industry. He is a passionate advocate for, and supporter of, the sector in Australia which fits well with the purpose and objectives of Medicines Australia.
“This is an important and challenging time for our members so having someone of Dr Cross’ calibre at the helm is exciting and I am sure he will serve our industry with distinction.”
Most recently, Dr Cross was Managing Director of Alphapharm, Chair of the Generic Medicines Industry Association and Chair of the Pharmaceutical Industry Council. He has previously been Managing Director of Novartis in Australia and a member of the Medicines Australia Board. He has also previously worked over many years for ICI, Zeneca and AstraZeneca, another Medicines Australia member company.
Medicines Australia Chief Executive, Dr Brendan Shaw, said he was delighted with the announcement.
“This is a great appointment,” Dr Shaw said.
“Martin and I have worked together on various industry issues over the years, so I’m looking forward to working with Martin to prosecute the range of issues on the agenda for Medicines Australia.
“I also want to acknowledge Mark Fladrich’s leadership of Medicines Australia over recent months while a search for a permanent Chair progressed and thank him for his contribution.”
Dr Cross’ appointment commences in early November. Mr Fladrich will continue as interim Chair of Medicines Australia until that time.
Phone: (02) 8281 3280